CA3177117A1 - Substituted benzotriazinone metabolites of a gpr139 agonist - Google Patents

Substituted benzotriazinone metabolites of a gpr139 agonist Download PDF

Info

Publication number
CA3177117A1
CA3177117A1 CA3177117A CA3177117A CA3177117A1 CA 3177117 A1 CA3177117 A1 CA 3177117A1 CA 3177117 A CA3177117 A CA 3177117A CA 3177117 A CA3177117 A CA 3177117A CA 3177117 A1 CA3177117 A1 CA 3177117A1
Authority
CA
Canada
Prior art keywords
oxo
trifluoromethoxy
ethyl
triazin
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177117A
Other languages
English (en)
French (fr)
Inventor
Amin Mohamed Kamel
Stephen Uriah Bowlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3177117A1 publication Critical patent/CA3177117A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CA3177117A 2020-05-08 2021-05-06 Substituted benzotriazinone metabolites of a gpr139 agonist Pending CA3177117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021895P 2020-05-08 2020-05-08
US63/021,895 2020-05-08
PCT/IB2021/000304 WO2021224680A1 (en) 2020-05-08 2021-05-06 Substituted benzotriazinone metabolites of a gpr139 agonist

Publications (1)

Publication Number Publication Date
CA3177117A1 true CA3177117A1 (en) 2021-11-11

Family

ID=76624075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177117A Pending CA3177117A1 (en) 2020-05-08 2021-05-06 Substituted benzotriazinone metabolites of a gpr139 agonist

Country Status (5)

Country Link
US (1) US12559465B2 (https=)
EP (1) EP4146635A1 (https=)
JP (1) JP7697974B2 (https=)
CA (1) CA3177117A1 (https=)
WO (1) WO2021224680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
US20230310441A1 (en) 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia

Also Published As

Publication number Publication date
US12559465B2 (en) 2026-02-24
JP7697974B2 (ja) 2025-06-24
EP4146635A1 (en) 2023-03-15
US20230227416A1 (en) 2023-07-20
WO2021224680A8 (en) 2023-01-05
WO2021224680A1 (en) 2021-11-11
JP2023524133A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
CA3177117A1 (en) Substituted benzotriazinone metabolites of a gpr139 agonist
CN109988109B (zh) 抑制ssao/vap-1的胺类化合物及其用途
EP3143020B1 (en) Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CA3119656A1 (en) Macrocyclic compounds and their use in the treatment of disease
CA3149963A1 (en) Heterocyclic rip1 kinase inhibitors
AU2019204244A1 (en) Cyclopropylamines as lsd1 inhibitors
CN102307868B (zh) 作为抗癌剂的吲哚衍生物
CN110177788A (zh) 作为bcl-2选择性凋亡诱导剂的化合物
EP3105219A1 (en) Cyclopropylamines as lsd1 inhibitors
CN113825754B (zh) 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
EP1870405A1 (en) Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2014137723A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112017002811B1 (pt) Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
TW201625305A (zh) 用於癌症治療之組合療法
NZ721723A (en) Tetrahydropyridopyrazines modulators of gpr6
WO2016007727A1 (en) Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN104854101A (zh) Alk激酶抑制剂
WO2025026392A1 (zh) 驱动蛋白kif18a抑制剂及其应用
US20070088021A1 (en) 4-haloisoquinoline derivative and drug containing the same
CN106414443B (zh) 吡啶并嘧啶二酮衍生物
CA3094481A1 (en) Phenothiazine derivatives and uses thereof
CN104334561A (zh) 化合物jk12a及其制备
CN103814025A (zh) 可用作胆碱激酶抑制剂的化合物
WO2024099411A1 (zh) 一种杂环类抗肿瘤化合物的盐及其晶型
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250714

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260309